Heart failure & cardiomyopathiesSecondary analysis
Effect of Long-Term Tafamidis Treatment on Health-Related Quality of Life in Patients with Transthyretin Amyloid Cardiomyopathy
- Secondary analysis of the ATTR-ACT randomised trial and its long-term extension study
Authors' conclusion
Tafamidis reduced HRQoL decline in patients with ATTR-CM. Patients continuously treated with tafamidis for 60 months demonstrated stabilized HRQoL. In patients who initially received placebo in ATTR-ACT, tafamidis reduced the decline in HRQoL during the LTE study.
Study context
- Population
- Patients with transthyretin amyloid cardiomyopathy (ATTR-CM) in ATTR-ACT and its long-term extension (LTE)
- Participants
- 176 vs 177
- Comparison
- Continuous tafamidis vs placebo then tafamidis
- Tafamidisn = 176
- Placebon = 177reference
- Primary endpoint
- Change from baseline in KCCQ-OS and KCCQ-CS scores
Primary result
As reported in the abstract
Change from baseline in KCCQ-OS (value) and KCCQ-CS scores · Month 30 (value); month 60 in measures
| Group | Value | KCCQ-CS, month 30 | Kansas City Cardiomyopathy Questionnaire overall summary (KCCQ-OS), month 60 | KCCQ-CS, month 60 |
|---|---|---|---|---|
| Tafamidis | Least squares (LS) mean −6.25 (SE 1.53) | −7.48 [1.39] | −5.92 [1.77] | −9.21 [1.88] |
| Placebo | LS mean −19.60 (SE 1.94) | −19.90 [2.01] | −24.70 [3.04] | −25.30 [3.36] |
Original publication
Effect of Long-Term Tafamidis Treatment on Health-Related Quality of Life in Patients with Transthyretin Amyloid Cardiomyopathy. Eur J Heart Fail. Published 4 March 2024. doi:10.1002/ejhf.3190
Summarised from the published abstract; every number is checked against it